Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Oropharyngeal cancer
Stage/Subtype:  stage III oropharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 83 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IV Oropharyngeal Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0825, NCI-2013-01879, NCT01893307
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Radiation Therapy with or without Cisplatin in Treating Patients with Oropharyngeal Cancer Previously Treated with Surgery
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 201207059, NCI-2012-01230, NCT01687413
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991004, NCI-2015-02263, 2015-002552-27, JAVELIN MEDLEY, NCT02554812
Vaccine Therapy and Cyclophosphamide in Treating Patients with Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J09100, NCI-2010-01868, CIR00005394, NA_00031401, NCT01088789
Intensity-Modulated Radiation Therapy in Treating Patients With Cancer of the Oropharynx
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: J0988, NCI-2009-01536, NCT01088802
Cetuximab Followed By Surgery and Chemoradiation Therapy in Treating Patients With Previously Untreated Stage III-IVA Head and Neck Squamous Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 08-013, NCI-2011-02479, NCT01218048
Cetuximab and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: UMCC 2009.009, NCI-2011-03619, HUM00027253, NCT01250522, NCT00904345
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
Start Over